GD2 is a disialoganglioside, a type of glycosphingolipid, that is expressed on the surface of various cells. It is notably present in high levels on neuroblastoma cells, melanoma cells, and certain types of sarcoma. This makes GD2 an excellent target for immunotherapy, particularly in cancer treatment.
